Oxford Biomedica plc (LON: OXB)

London flag London · Delayed Price · Currency is GBP · Price in GBX
418.50
-8.00 (-1.88%)
Dec 23, 2024, 1:42 PM BST
107.69%
Market Cap 451.83M
Revenue (ttm) 97.28M
Net Income (ttm) -142.02M
Shares Out 105.94M
EPS (ttm) -1.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 44,182
Open 423.00
Previous Close 426.50
Day's Range 418.50 - 429.00
52-Week Range 167.00 - 450.00
Beta 1.09
Analysts n/a
Price Target n/a
Earnings Date Dec 24, 2024

About Oxford Biomedica

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and de... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 703
Stock Exchange London Stock Exchange
Ticker Symbol OXB
Full Company Profile

Financial Performance

In 2023, Oxford Biomedica's revenue was 89.54 million, a decrease of -36.04% compared to the previous year's 139.99 million. Losses were -157.49 million, 302.2% more than in 2022.

Financial Statements

News

Small Cap Stocks: Oxford Biomedica, Mirriad, United Oil & Gas

Oxford Biomedica, Mirriad Advertising, Invinity Energy, United Oil & Gas, SysGroup are today's biggest Small Cap stock movers

19 days ago - The Armchair Trader

Half Year 2024 Oxford Biomedica PLC Earnings Call Transcript

Half Year 2024 Oxford Biomedica PLC Earnings Call Transcript

3 months ago - GuruFocus

Three Quick Facts: Oxford Biomedica, Rightmove, Galliford Try

Oxford Biomedica, Rightmove, Galliford Try are Tony Cross's three picks from today's financial market news

3 months ago - The Armchair Trader

Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO

Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO

3 months ago - GlobeNewsWire

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and innov...

4 months ago - GlobeNewsWire

Oxford Biomedica announces CFO transition

Oxford Biomedica announces Chief Financial Officer transition - Lucinda Crabtree to join as Chief Financial Officer - Oxford, UK – 17 July 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OX...

5 months ago - GlobeNewsWire

Oxford Biomedica plc (OXBDF) Q4 2023 Earnings Call Transcript

Oxford Biomedica plc (OTCPK:OXBDF) Q4 2023 Earnings Conference Call April 29, 2024 8:00 AM ET Company Participants Frank Mathias - Chief Executive Officer Sébastien Ribault - Chief Commercial Officer ...

8 months ago - Seeking Alpha

Oxford Biomedica completes acquisition of ABL Europe

Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica's position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites...

11 months ago - GlobeNewsWire

Oxford Biomedica is hosting a free webinar to share clients' success stories in viral vector manufacturing

Oxford Biomedica is hosting a free webinar to share clients' success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and innova...

11 months ago - GlobeNewsWire

Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO

Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO

1 year ago - GlobeNewsWire

Oxford Biomedica plc (OXBDF) Q2 2023 Earnings Call Transcript

Oxford Biomedica plc (OTCPK:OXBDF) Q2 2023 Earnings Conference Call September 20, 2023 8:00 AM ET Company Participants Frank Mathias - CEO Sebastien Ribault - Chief Commercial Officer Stuart Paynter -...

1 year ago - Seeking Alpha

Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform

The non-exclusive, multi-year license and supply agreement enables use of LentiVector ® with any Kyverna product Agreement supports Kyverna's scalability and reliability of CAR T cell manufacturing go...

1 year ago - PRNewsWire

Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domest...

1 year ago - GlobeNewsWire

Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domest...

1 year ago - GlobeNewsWire

Oxford Biomedica stock soars on rosy forecast, talks to buy ABL Europe

Oxford Biomedica's shares jumped as much as 16% on Wednesday after the British cell and gene therapy company said it would break even earlier than expected and that it was in exclusive talks to buy vi...

1 year ago - Reuters

Oxford Biomedica to host webinar showcasing the TetraVecta™ system

Oxford Biomedica to host webinar s howcas ing the TetraVect a TM system

1 year ago - GlobeNewsWire

Oxford Biomedica Solutions Publishes Peer-Reviewed Journal Article On Novel Dual-Plasmid System, Resulting In Significantly Increased AAV Vector Productivity And Percentage Of Full Capsids Packaged

BEDFORD, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Oxford Biomedica Solutions LLC, offers The Full Solution™ suite of services, which includes end-to-end development and manufacturing capabilities for ...

1 year ago - GlobeNewsWire

Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system

Oxford Biomedica launches TetraVecta TM - the next generation lentiviral vector system

1 year ago - GlobeNewsWire

Oxford Biomedica Solutions to Present Company Capabilities and its Platform at American Society of Gene and Cell Therapy in Los Angeles

BEDFORD, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Oxford Biomedica Solutions LLC, offers The Full Solution™ services, which includes end-to-end development and manufacturing capabilities. The scientifi...

1 year ago - GlobeNewsWire

Oxford Biomedica plc (OXBDF) Q4 2022 Earnings Call Transcript

Oxford Biomedica plc (OXBDF) Q4 2022 Earnings Call Transcript.

1 year ago - Seeking Alpha

Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023

Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023

2 years ago - GlobeNewsWire

Oxford Biomedica Solutions forms new partnerships with three biotechnology companies

Agreements signed with three new partners, bringing the total number of new partners in 2022 to four, ahead of original target Agreements signed with three new partners, bringing the total number of n...

2 years ago - GlobeNewsWire

Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domest...

2 years ago - GlobeNewsWire

Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million

Oxford Biomedica to complete s ale and leaseback of Windrush Court facility for £60 million

2 years ago - GlobeNewsWire